Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $65.00


Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective raised by equities research analysts at Barclays from $58.00 to $65.00 in a research report issued on Wednesday, The Fly reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective points to a potential upside of 35.30% from the stock’s current price.

Several other research analysts have also recently issued reports on the company. BMO Capital Markets cut their target price on Agios Pharmaceuticals from $57.00 to $50.00 in a research report on Wednesday, December 9th. Canaccord Genuity cut their price objective on Agios Pharmaceuticals from $70.00 to $57.00 and set a “buy” rating on the stock in a research report on Monday, December 28th. Piper Sandler boosted their price objective on Agios Pharmaceuticals from $73.00 to $80.00 in a research report on Monday, December 21st. Needham & Company LLC cut their price objective on Agios Pharmaceuticals from $71.00 to $69.00 and set a “buy” rating on the stock in a research report on Monday, October 19th. Finally, Royal Bank of Canada cut their price objective on Agios Pharmaceuticals from $59.00 to $66.00 in a research report on Tuesday, December 22nd. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $65.50.

Agios Pharmaceuticals stock remained flat at $$48.04 during mid-day trading on Wednesday. The company’s stock had a trading volume of 4,519 shares, compared to its average volume of 820,171. Agios Pharmaceuticals has a 12-month low of $27.77 and a 12-month high of $56.74. The company has a fifty day simple moving average of $42.42 and a 200-day simple moving average of $41.64. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -9.78 and a beta of 1.80.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($1.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.36) by ($0.07). The company had revenue of $34.70 million for the quarter, compared to analysts’ expectations of $38.12 million. Agios Pharmaceuticals had a negative net margin of 170.65% and a negative return on equity of 57.63%. The firm’s quarterly revenue was up 33.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.81) EPS. As a group, equities research analysts predict that Agios Pharmaceuticals will post -4.75 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the business. Capital International Sarl raised its stake in shares of Agios Pharmaceuticals by 3.3% in the third quarter. Capital International Sarl now owns 8,198 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 264 shares during the period. Public Employees Retirement System of Ohio raised its stake in shares of Agios Pharmaceuticals by 4.0% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 24,351 shares of the biopharmaceutical company’s stock valued at $852,000 after purchasing an additional 927 shares during the period. Advisor Group Holdings Inc. raised its stake in shares of Agios Pharmaceuticals by 427.9% during the 2nd quarter. Advisor Group Holdings Inc. now owns 1,267 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 1,027 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Agios Pharmaceuticals by 9.2% during the 3rd quarter. Virtus ETF Advisers LLC now owns 12,398 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 1,044 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in shares of Agios Pharmaceuticals by 1,186.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,672 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,542 shares during the period. Hedge funds and other institutional investors own 92.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.

Further Reading: How mutual funds make money

The Fly

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.